Background: The variable efficacy (0-80%) of Mycobacterium bovis Bacille Calmette Gurein (BCG) vaccine against adult tuberculosis (TB) necessitates development of alternative vaccine candidates. Development of recombinant BCG (rBCG) over-expressing promising immunodominant antigens of M. tuberculosis represents one of the potential approaches for the development of vaccines against TB.
Type
research article
Web of Science ID
WOS:000265452200013
Author(s)
Jain, Ruchi
Dey, Bappaditya
Dhar, Neeraj
Rao, Vivek
Singh, Ramandeep
Gupta, Umesh D.
Katoch, V. M.
Ramanathan, V. D.
Tyagi, Anil K.
Date Issued
2008
Publisher
Published in
Volume
3
Issue
12
Article Number
e3869
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
November 30, 2010
Use this identifier to reference this record